viewNovartis AG (ADR)

Cerulean Pharma shares soar after news of Novartis tie-up

The struggling microcap has signed a discovery and development deal with a giant of the pharmaceutical industry

cancer cells under a microscope
Cerulean focuses on finding treatments for various cancers

Shares in cancer drug discovery firm Cerulean Pharma Inc (NASDAQ:CERU) soared after it announced that it had teamed up with pharmaceutical giant Novartis (NYSE:NVS) in a discovery and development deal.

Novartis is buying into the promise of Cerulean’s nanoparticle drug conjugates (NDCs) and is making an upfront payment of US$5mln as well as funding the first five candidates.

Long term investor Aspire Capital has also committed to ploughing US$20mln into the struggling microcap.

Under the terms of the deal, Cerulean’s Dynamic Tumour Targeting technology will be combined with Novartis’ compounds against up to five targets.

Cerulean is to create the NDCs, with Novartis being responsible for further development and the commercialisation of the products.

“Novartis is widely recognised as one off the world leaders in drug development,” said Cerulean President Christophe Guiffre.

“This collaboration is further validation of out powerful technology platform, and we are excited that Novartis is including NDCs in its drug discovery and development efforts.”

In addition to the upfront payment, Cerulean is also eligible for cash boosts if, or when, it hits certain preclinical, clinical, regulatory and sales milestones for each target.

Cerulean has endured a difficult time since it listed on NASDAQ back in 2014.

The stock hit a high of US$10 last year, but fell below a buck this summer after its lead candidate CRLX101 failed in a combination trial to beat treatment of care in the treatment of renal cell carcinoma.

The company then pretty much slashed its workforce in half following the failure.

Shares in Cerulean climbed 53% to US$1.04, while Novartis dipped slightly to trade at US$76.

Quick facts: Novartis AG (ADR)

Price: 95.63 USD

Market: NYSE
Market Cap: $217.51 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Ora Banda Mining anticipating its first gold bar by the end of January

Ora Banda Mining Ltd's (ASX:OBM) David Quinlivan talks Proactive's Andrew Scott through its December quarterly update. He says they've now begun wet commissioning of the plant and will be progressively commissioning over the coming weeks with a view of getting the first gold bar out by the end...

14 hours, 43 minutes ago

2 min read